The significant weight loss and metabolic improvements observed with retatrutide, coupled with its acceptable safety profile, highlight its potential to address unmet medical needs in obesity treatment
Treatment is guided by a licensed provider and tailored to individual recovery needs
Editor: Hira Rafi, Northwestern University Feinberg School of Medicine, UNITED STATES OF AMERICA Received: September 3, 2025
Patients previously experiencing gastrointestinal symptoms from GLP-1 receptor agonists, including nausea, vomiting, or abdominal distension, have a greater risk of increased residual gastric contents and should be treated as if they had a full stomach, regardless of fasting
The Lancet , 389 (10085), 19952005
Expression and distribution of glucagon-like peptide1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain